{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:57:49Z","timestamp":1790135869977,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with generalized myasthenia gravis (gMG) frequently have variable and fluctuating symptoms. Treatments providing long\u2010term, sustained disease control are essential for improving function and health\u2010related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the phase 3 Vivacity\u2010MG3\u00a0study, nipocalimab improved clinical outcomes in adults with gMG when added to standard\u2010of\u2010care (SOC) therapy. These post hoc analyses further assessed the ability of nipocalimab to produce sustained responses over 24\u2009weeks, using the following response categories for total score improvements in Myasthenia Gravis\u2010Activities of Daily Living (MG\u2010ADL) and Quantitative Myasthenia Gravis (QMG), respectively: Meaningful Clinical Improvement (MCI; \u2265\u20092\u2010 and \u2265\u20093\u2010point), Substantial Improvement (SI; \u2265\u20093\u2010 and \u2265\u20094\u2010point), Considerable Improvement (CIP; \u2265\u20094\u2010 and \u2265\u20095), Composite Response (CR; MG\u2010ADL improvement \u2265\u20092\u2010points plus QMG improvement \u2265\u20093\u2010points), and Minimal Symptom Expression (MSE; MG\u2010ADL 0 or 1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significantly higher percentages of nipocalimab\u2010treated than placebo\u2010treated participants achieved MG\u2010ADL MCI, SI, and CIP, sustained for \u2265\u200912 consecutive weeks; achievement of these outcomes occurred as early as week 1 among nipocalimab\u2010treated participants. Similar results were observed for QMG MCI, SI, and CIP. Significantly higher percentages of nipocalimab\u2010treated participants achieved CR, sustained for \u2265\u20098 consecutive weeks versus placebo; the likelihood of achieving sustained CR for \u2265\u20098\u2009weeks was higher with nipocalimab (odds ratio\u2009=\u20096.3). Nipocalimab\u2010treated participants were 4\u2010fold more likely to achieve MSE, sustained for \u2265\u20098 consecutive weeks versus placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022). MSE and CR were achieved earlier among nipocalimab\u2010treated participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nipocalimab treatment improves gMG symptoms earlier than placebo and provides meaningful and long\u2010term sustained disease control over 24\u2009weeks among participants with gMG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70599","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:14:24Z","timestamp":1779257664000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity\u2010\n                    <scp>MG3<\/scp>\n                    Study"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0210","authenticated-orcid":false,"given":"Tuan","family":"Vu","sequence":"first","affiliation":[{"name":"Department of Neurology University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said R.","family":"Beydoun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keck Medicine of USC University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Neurology Yale University School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Katzberg","sequence":"additional","affiliation":[{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ait\u2010Tihyaty","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Pease","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie","family":"Sattin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-9200","authenticated-orcid":false,"given":"Sindhu","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.21307\/ajon-2017-112"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00285-w"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00408-x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28063"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211065406"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.12.003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501561"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28233"},{"key":"e_1_2_10_25_1","unstructured":"Janssen Pharmaceutical Companies \u201cIMAAVY (nipocalimab\u2010aahu) injection for intravenous use. Full Presctribing Information \u201d(2025) https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/IMAAVY\u2010pi.pdf."},{"key":"e_1_2_10_26_1","unstructured":"European Medicines Agency \u201cImaavy. European Medicines Agency \u201d(2025) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imaavy."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.006"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23988"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-03982-3"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21609"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09770-y"},{"key":"e_1_2_10_38_1","unstructured":"argenx BV \u201cVYVGART(efgartigimod alfa\u2010fcab) injection for intravenous use Prescribing Information \u201d(2025) https:\/\/argenx.com\/content\/dam\/argenx\u2010corp\/products\/vyvgart\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_10_39_1","unstructured":"UCB Inc \u201cRYSTIGGO (rozanolixizumab\u2010noli) injection for subcutaneous use. Prescribing Information \u201d(2025) https:\/\/www.ucb\u2010usa.com\/RYSTIGGO\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_10_40_1","unstructured":"A. A.Habib T.Vu K.Utsugisawa et\u00a0al. \u201cRozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis. MGFA Scientific Session at AANEM 2024; Savannah GA USA; October 15 2024 \u201d(2024) https:\/\/www.ucbcompass.com\/sites\/default\/files\/2024\u201011\/Habib_MGFA%20SS%202024%20MycarinG%20Treatment%20Patterns%20poster%20Submission_V2.pdf."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"key":"e_1_2_10_42_1","unstructured":"Food and Drug Administration \u201cPlan for Issuance of Patient\u2010Focused Drug Development Guidance: Under 21st Century Cures Act Title III Section\u00a03002 \u201d(2017) https:\/\/www.fda.gov\/media\/105979\/download."}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70599","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:08:42Z","timestamp":1779970122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/ene.70599"],"URL":"https:\/\/doi.org\/10.1111\/ene.70599","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70599"}}